GSK "GOLUBINO", Moscow

Economic indicators

Net loss (RAS) of GSK GOLUBINO dropped over 2023 8.28 times to 39.00 thousand RUB from 323.00 thousand RUB KAgent.Entities.Balance, the company informed.

Revenue decreased in the accounting period by 14.16% to 7.03 million RUB from 8.19 million RUB in 2022.

Net loss (RAS) of GSK GOLUBINO dropped over 2022 by 36.91% to 323.00 thousand RUB from 512.00 thousand RUB KAgent.Entities.Balance, the company informed.

Revenue decreased in the accounting period 2.77 times to 8.19 million RUB from 22.70 million RUB in 2021.

Net loss (RA) of GSK GOLUBINO made up 512.00 thousand RUB over 2021 compared to net profit of 1.61 million RUB over 2020, the company informed.

Revenue increased in the accounting period by 21.77% to 22.70 million RUB from 18.64 million RUB over 2020.

Net profit (RAS) of GSK GOLUBINO made up 1.61 million RUB over 2020 compared to net loss of 210.00 thousand RUB over 2019, the company informed.

Revenue decreased in the accounting period by 9.94% to 18.64 million RUB from 20.69 million RUB in 2019.

Net loss (RA) of GSK GOLUBINO made up 210.00 thousand RUB over 2019 compared to net profit of 357.00 thousand RUB over 2018, the company informed.

Revenue increased in the accounting period by 4.19% to 20.69 million RUB from 19.86 million RUB over 2018.

Net profit (RAS) of GSK GOLUBINO dropped in 2018 5.53 times to 357.00 thousand RUB from 1.98 million RUB over the same period in 2017, the company informed.

Revenue increased in the accounting period by 8.64% to 19.86 million RUB from 18.28 million RUB over 2017; cost of goods sold grew by 17.71% to 19.45 million RUB from 16.52 million RUB; sales profit fell 4.28 times to 411.00 thousand RUB from 1.76 million RUB.

Net profit (RAS) of GSK GOLUBINO grew over 2017 by 32.82% to 1.98 million RUB from 1.49 million RUB over 2016, the company informed.

Revenue decreased in the accounting period by 6.68% to 18.28 million RUB from 19.59 million RUB in 2016; cost of goods sold decreased by 8.84% to 16.52 million RUB from 18.13 million RUB; sales profit went up by 20.07% to 1.76 million RUB from 1.47 million RUB.

Net profit (RAS) of GSK GOLUBINO dropped in 2016 2.05 times to 1.49 million RUB from 3.05 million RUB over the same period in 2015, the company informed.

Revenue decreased in the accounting period by 14.91% to 19.59 million RUB from 23.02 million RUB in 2015; cost of goods sold decreased by 9.41% to 18.13 million RUB from 20.01 million RUB; sales profit fell 2.06 times to 1.47 million RUB from 3.02 million RUB.

Net profit (RAS) of GSK GOLUBINO grew over 2014 by 24.22% to 5.26 million RUB from 4.24 million RUB over 2013, the company informed.

Revenue increased in the accounting period by 15.43% to 20.84 million RUB from 18.05 million RUB over 2013; cost of goods sold grew by 13.59% to 15.73 million RUB from 13.85 million RUB; sales profit went up by 21.51% to 5.11 million RUB from 4.20 million RUB.

Net profit (RAS) of GSK GOLUBINO grew over 2013 by 31.87% to 4.24 million RUB from 3.21 million RUB over 2012, the company informed.

Revenue increased in the accounting period by 1.96% to 18.05 million RUB from 17.70 million RUB over 2012; cost of goods sold decreased by 5.58% to 13.85 million RUB from 14.67 million RUB; sales profit went up by 38.39% to 4.20 million RUB from 3.04 million RUB.

Companies in the region

• IRBISSTROYINVEST
• PRAVOSL RELIG OBSCHINA VELIKOMUCH PANTELEIMONA
• STROYINVEST MAKSIMA
• UDACHA
• TRAST-STROY